Skip to main content
Fig. 3 | World Journal of Surgical Oncology

Fig. 3

From: Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review

Fig. 3

Overall survival (OS) at 1 year and 2 years as reported in trials of Gliadel wafers combined with standard radiotherapy (RT) and concurrent followed by adjuvant temozolomide (TMZ) for the treatment of high-grade glioma. The 1-year and 2-year OS values of these trials are compared with the values for the active treatment arm of the 240-patient phase III clinical trial of Gliadel wafers plus RT [8, 10] (column 1) and the active treatment arm of the phase III clinical trial of RT/TMZ (column 2) [11, 12]

Back to article page

World Journal of Surgical Oncology

ISSN: 1477-7819

Contact us